The Belgian Hematology Society (BHS), with the support of an unrestricted grant from Gilead Sciences and Kite, a Gilead company, has the pleasure to announce two grants to support research in the field of cellular therapies in hematological disease.
PROJECT SUBMISSION IS NOW CLOSED
Researchers working in hematology are invited to submit their project and apply for the Gilead Cell Therapy Grants. All information on rules and regulations are available on the homepage , as is the application form.
The deadline for submission is 1 December 2021, midnight.
The jury will select two winning projects based on their innovative character, which will be awarded with EUR 25.000. The award ceremony will take place at the 37th BHS General Annual Meeting, February 4-5, 2022.
We are looking forward to receiving outstanding projects that can advance the outcomes of hematological diseases through cellular therapies.
Ann Janssens, President of the BHS
PARTICIPATION REQUIREMENTS "GILEAD AWARD" 2022
Who can apply?
- Any researcher working on cellular therapies in hematological malignancies can apply.
Which projects are eligible?
- The topic of research is related to translational research within the field of cellular therapies in hematology. Innovative research on autologous or allogeneic stem cell transplant is also considered in scope.hematology.
- Description of the research project including costs and timeframe (max. 2 pages) - Example project submission GILEAD award 2022.docx
- Letter of support by a promotor from the department where the research will be performed (max. 1 page)
- Motivational letter (max. 1 page)
- List of publications (if applicable)
Only submission through the online tool is possible. Submissions sent by e-mail will not be considered.
Candidates working at a pharmaceutical company are excluded.
A monetary grant of EUR 25.000 will be awarded to the winner. The results of the selection will be announced during the 2022 General Annual Meeting of the BHS. This award has been made possible with an unrestricted grant from Gilead Sciences Belgium.
Inge Govaerts, UZ Leuven/KU Leuven
|In-depth investigation of CAR T-cell behaviour to predict complications and outcome|
Virginie Chapelle, Cliniques universitaires Saint-Luc
|Immunomonitoring during CAR-T cell therapy project : Interest of molecular biology and flow cytometry|
||Prognosis and immuno-therapeutical role of circulating miRNAs in acute myeloid leukaemia (AML) allogeneic transplantation and cellular immunotherapy treatment optimisation
||Antigen-specific Non-signaling CARs as Hemato-Oncological Remedy (ANCHOR project)